Trial | NCT01575340  Report issue

Title

Study to Assess the Effect of Consumption of Fish Oil Encapsulated on Inflammatory Markers in Colorectal Cancer
Markers of the Inflammatory Response (IL-1β, IL-10, IL-17A and TNF-α) in Patients With Colorectal Cancer in Chemotherapy Supplemented With Fish Oil

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    fish oil ...

  • Study Participants

    11
The purpose of this study is to evaluate whether supplementation 2g/day encapsulated fish oil modifies inflammatory markers in individuals with colorectal cancer in chemotherapy
The study will recruit patients with newly diagnosed colorectal cancer and that has not yet undergone any chemotherapy treatment. Individuals that meet the inclusion criteria are randomized by means of a computer program on two study groups: 1) supplemented Experimental: receive 2g/day supplementation encapsulated fish oil for 9 weeks. 2) No intervention - control: not receive supplementation of fish oil or placebo. Will be assessed the effects of supplementation on the standard profile of cytokine production, nutritional status, and proportion of incorporation of these fatty acids in blood cells (mononuclear and red blood cells).

Blood samples are collected before the start of first chemotherapy and nine weeks later. Supplementation in the experimental group also will start on the first day of chemotherapy.
Study Started
Jul 31
2011
Primary Completion
May 31
2012
Study Completion
Jul 31
2012
Last Update
Sep 06
2012
Estimate

Dietary Supplement fish oil encapsuled

2 g/d (4 capsules of 500 mg)for 9 weeks

  • Other names: omega-3 encapsuled

fish oil encapsuled Experimental

will receive the supplementation of 2 g / day of fish oil encapsulated for 9 weeks

without supplementation No Intervention

not will receive supplementation or encapsulated fish oil or placebo

Criteria 

Inclusion Criteria:

Age ≥ 19 years
Histopathological diagnosis of colorectal cancer
Beginning of chemotherapy in the target institution
Agree to participate in the study [signature of IC]

Exclusion Criteria:

Age <19 years
Being in palliative care
Inability to oral intake
Allergic to the fish and fish products
Owning with hyperlipidemia requiring drug treatment
Consumption prior to the study of fish oil or supplements containing omega-3 PUFA
Being in medical treatment with some nonsteroidal anti-inflammatory
Have some kind of infection
No Results Posted